Research programme: cancer therapeutics - UCB

Drug Profile

Research programme: cancer therapeutics - UCB

Latest Information Update: 16 Oct 2015

Price : $50

At a glance

  • Originator UCB Pharma SA
  • Developer WILEX AG
  • Class Antibodies
  • Mechanism of Action Immunomodulators; Phosphatidylinositol 3 kinase alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 14 Apr 2014 Discontinued - Preclinical for Cancer in Germany (Parenteral)
  • 14 Apr 2014 Discontinued - Preclinical for Cancer in Germany (PO)
  • 11 Jul 2013 Preclinical trials in Cancer in Germany (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top